Aurinia Pharmaceuticals (AUPH) investor relations material

Executive summary

• The annual general meeting will be held virtually on June 3, 2026, with shareholders voting on director elections, auditor appointment, and executive compensation on a non-binding advisory basis.

• Only shareholders of record as of April 14, 2026, are entitled to vote, with multiple voting methods available, including online, telephone, and mail.

• Proxy materials are distributed electronically, with paper copies available upon request, and the company encourages advance voting.

Voting matters and shareholder proposals

• Shareholders will vote to elect five director nominees, approve PricewaterhouseCoopers LLP as auditor, and provide a say-on-pay advisory vote on executive compensation.

• No shareholder proposals or third-party director nominations were received for this meeting.

• Advance notice provisions and universal proxy rules govern director nominations, with specific deadlines for future meetings.

Board of directors and corporate governance

• The board consists of five members, with 80% considered independent; the CEO also serves as Chair, with a Lead Independent Director appointed.

• All board committees (Audit, Compensation, Governance & Nomination) are wholly independent and have written charters.

• Annual board and committee self-evaluations are conducted, and there is regular director refreshment.

• The board met 12 times in 2025, with high attendance from all directors.